Clinical Study of Safety and Tolerability of CBLB502 as a Neo-adjuvant Treatment in Patients With Colorectal Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE2

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-11-30

Study Completion Date

2017-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Randomized Single-blind Placebo-controlled Clinical Study of Safety and Tolerability of CBLB502 as a Neo-adjuvant Treatment in Patients With Colorectal Cancer, With Different Doses and Regimens

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safety and Efficacy Study of BMS-908662 Alone or in Combination With Cetuximab in Subjects With K-RAS or B-RAF Mutation Positive Advanced or Metastatic Colorectal Cancer

NCT01086267

Colorectal Cancer

COMPLETED PHASE1/PHASE2

Evaluating the Safety and Efficacy of SB Injection in Patients With Advanced or Metastatic Colorectal Cancer

NCT01305980

Colorectal Cancer

UNKNOWN PHASE2

Asian Subjects With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy

NCT01584830

Colorectal Neoplasms

COMPLETED PHASE3

Nintedanib (BIBF 1120) vs Placebo in Refractory Metastatic Colorectal Cancer (LUME-Colon 1)

NCT02149108

Colorectal Neoplasms

COMPLETED PHASE3

Clinical Study of Irinotecan Liposome (II)-Based Combination Treatment for Irinotecan-resistant Colorectal Cancer.

NCT07044921

Colorectal Cancer Metastatic

RECRUITING PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Colorectal Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

CBLB502

Intervention Type DRUG

Placebo

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Entolimod PBS Phosphate buffer saline

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Written Patient Informed Consent for participation in the study
2. Men and women in the age above 18 years
3. Patients with confirmed diagnosis of colorectal cancer, indication to scheduled surgery for primary tumor removal
4. Should not have any previous anticancer therapy
5. Patient's life expectancy more than 3 months
6. ECOG performance status 0-1
7. Adequate hepatic and renal function:

* Total bilirubin ≤1.5 upper limit of normal (ULN)),
* Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 x ULN, regardless of the presence of liver metastases,
* Creatinine ≤2 x ULN
8. Adequate cardiac function including:

* LVEF ≥45 by echocardiogram (ECHO) or multi gated acquisition scan,
* 12-lead electrocardiogram (ECG) with normal tracing or non-clinically significant changes that do not require medical intervention,
* QTcB interval QT (QTc by Bazett's formula) \< 470 msec and no history of Torsades des Pointes or other symptomatic QTcB abnormality,
* Absence of orthostatic hypotonia
9. Negative testing for serological markers of HIV-infection, viral hepatitis В and С, syphilis
10. Content to use barrier contraception methods by male/female patient and his/her partner in the study period

Exclusion Criteria

1. Inability to obtain written Informеd consent for participation in the study
2. History of cardiovascular abnormalities including any conditions stated below:

* Myocardial infarction/stroke for the last 6 months,
* Stable abnormalities in regional contractility,
* Cardiac failure (NYHA functional class III-IV),
* Confirmed cardiomyopathy,
* Clinically significant arrhythmias including any conditions stated below:

* QT prolongation syndrome,
* History of II or III-degree AV-block,
* Bradycardia (HR \< 50 beats per min.) or tachycardia (HR \>100 beats per min.)
* Blood pressure abnormalities:

* 2 degree uncontrolled arterial hypertension (systolic blood pressure \> 160 mm Hg or diastolic blood pressure \> 105 mm Hg),
* Hypotension (systolic blood pressure \< 90 mm Hg)
3. History of severe allergic, systemic and other oncologic diseases
4. Decompensated diabetes mellitus with glycolated hemoglobin level (HbA1c) \> 7%
5. Administration of drug products with evident effect on immune system for previous 3 months prior screening (including corticosteroids. Remark: Topical agents (e.g. for rash treatment), inhalation aerosols (e.g. for treatment of broncho-obstructive diseases), eye drops and agents for local administration (e.g. to joint cavity) is allowed
6. Participation in other clinical studies or administration of study products for 30 days prior screening, or persisting adverse reactions of the study product
7. Patients that have not taken CBLB502
8. Patients with hypersensitivity/allergy to CBLB502 or excipients of the drug product; NSAID (including ibuprofen)
9. Pregnant or lactating women
10. History of salmonellosis
11. Body mass \> 88 kg; no obesity which means BMI in the range 18.5-25 kg/m2 for women and 22-27 kg/m2 for men
12. Men and women of childbearing age which do agree to use double contraception method, oral contraception or abstain from sex contacts throughout the study
13. Alcohol abuse, drug abuse and any other medical, psychological and social reasons which may, in accordance with the investigator, affect patient's participation in the study, may prevent adequate assessment of the study results
14. Any conditions which are unstable or may endanger patient's safety and/or affect his/her adherence to the investigator instruction
15. Any patient is not able or willing to cooperate with the investigator

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No